Salis M, Kandemir M, Gundogdu E, Ozer I, Unal B, Ulas M
Turk J Surg. 2025; 40(3):261-263.
PMID: 39917408
PMC: 11792906.
DOI: 10.47717/turkjsurg.2022.4595.
Petrillo A, Ottaviano M, Pompella L, Giunta E, Pisapia P, Marte G
Ther Adv Med Oncol. 2025; 17:17588359241255628.
PMID: 39867743
PMC: 11760139.
DOI: 10.1177/17588359241255628.
Lei X, Su Y, Lei R, Zhang D, Liu Z, Li X
Front Endocrinol (Lausanne). 2025; 15():1488733.
PMID: 39839478
PMC: 11746099.
DOI: 10.3389/fendo.2024.1488733.
Halperin R, Tirosh A
Fam Cancer. 2025; 24(1):15.
PMID: 39826015
PMC: 11742904.
DOI: 10.1007/s10689-025-00440-4.
Hammel P, Smith D, Afchain P, Dominguez-Tinajero S, Seitz J, Lievre A
Ther Adv Med Oncol. 2024; 16:17588359241290140.
PMID: 39563716
PMC: 11574894.
DOI: 10.1177/17588359241290140.
Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.
Kasai Y, Ito T, Masui T, Nagai K, Anazawa T, Uchida Y
J Gastroenterol. 2024; 60(1):1-9.
PMID: 39547997
PMC: 11717855.
DOI: 10.1007/s00535-024-02166-z.
Prognostic prediction and treatment options for gastric signet ring cell carcinoma: a SEER database analysis.
Yu C, Yang J, Li H, Wang J, Jin K, Li Y
Front Oncol. 2024; 14:1473798.
PMID: 39497709
PMC: 11532132.
DOI: 10.3389/fonc.2024.1473798.
A Novel Liver Metastasis Score for Patients Undergoing Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: A Multi-institutional Study.
Zheng Q, Xu J, Yang F, Liu Z, Wang M, Hao Y
Ann Surg Oncol. 2024; 32(2):1176-1186.
PMID: 39480603
DOI: 10.1245/s10434-024-16389-0.
Immune checkpoint inhibitor therapy for primary neuroendocrine carcinoma of the gallbladder: A case report and literature review.
Li C, Lv P, Yanyan L, Yin M, Li H
Medicine (Baltimore). 2024; 103(43):e40178.
PMID: 39470513
PMC: 11521044.
DOI: 10.1097/MD.0000000000040178.
Gastroenteropancreatic Neuroendocrine Tumor with Peritoneal Metastasis: A Review of Current Management.
Hounschell C, Higginbotham S, Al-Kasspooles M, Selby L
Cancers (Basel). 2024; 16(20).
PMID: 39456565
PMC: 11506451.
DOI: 10.3390/cancers16203472.
Evaluation of selected circulating cytokines from the IL-6 family - interleukin 6, oncostatin M, and cardiotrophin-1 - in gastro-entero-pancreatic and bronchial neuroendocrine tumours.
Strzelczyk J, Janas K, Strzelczyk J, Chelmecka E, Kajdaniuk D, Kos-Kudla B
Contemp Oncol (Pozn). 2024; 28(2):114-120.
PMID: 39421708
PMC: 11480914.
DOI: 10.5114/wo.2024.142584.
Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment.
Tan B, Zhang B, Chen H
Front Endocrinol (Lausanne). 2024; 15:1424839.
PMID: 39411312
PMC: 11474919.
DOI: 10.3389/fendo.2024.1424839.
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN),....
Panzuto F, Albertelli M, De Rimini M, Rizzo F, Grana C, Cives M
J Endocrinol Invest. 2024; 48(1):23-36.
PMID: 39395114
PMC: 11729074.
DOI: 10.1007/s40618-024-02448-6.
Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors.
Hlongwa K, Kolade O, Alnabulsi A, Steyn R, Brink A, Prasad V
Front Nucl Med. 2024; 3:1193880.
PMID: 39355026
PMC: 11440991.
DOI: 10.3389/fnume.2023.1193880.
Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Kiesewetter B, Pfluger F, Melhorn P, Mazal P, Raderer M
Clin Transl Oncol. 2024; .
PMID: 39316250
DOI: 10.1007/s12094-024-03732-w.
Survival impact of [Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases.
Lugat A, Chouin N, Chocteau F, Esnault M, Marionneau-Lambot S, Gouard S
Eur J Nucl Med Mol Imaging. 2024; 52(2):730-743.
PMID: 39269657
DOI: 10.1007/s00259-024-06918-0.
Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
Chen J, Bai L, Cheng H, Chan S, Zou J, Shi X
Oncol Ther. 2024; 13(1):69-83.
PMID: 39215958
PMC: 11880440.
DOI: 10.1007/s40487-024-00302-6.
Clinical and pathological characteristics of and predictive model for colorectal neuroendocrine tumors.
Ma J, Ma X, Xing J, Song R, Zhang Y, Liu M
Heliyon. 2024; 10(15):e35720.
PMID: 39170272
PMC: 11336838.
DOI: 10.1016/j.heliyon.2024.e35720.
Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.
Doello K, Chico M, Quinonero F, Ortiz R, Prados J, Mesas C
Medicina (Kaunas). 2024; 60(7).
PMID: 39064468
PMC: 11279282.
DOI: 10.3390/medicina60071039.
Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut.
Garcia-Torralba E, Garcia-Lorenzo E, Doger B, Spada F, Lamarca A
Cancers (Basel). 2024; 16(14).
PMID: 39061170
PMC: 11275146.
DOI: 10.3390/cancers16142530.
